Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/12/2025

Management of Reactive Airway Disease Without Wheezing

Diagnosis Considerations

  • The American Thoracic Society suggests that cough variant asthma should be considered when cough is the predominant symptom without wheeze, with symptoms including shortness of breath, chest tightness, and cough that are variable, intermittent, worse at night, and provoked by triggers including exercise 1, 3
  • Objective testing is essential as airflow limitation may be normal between episodes of bronchospasm, with peak expiratory flow (PEF) monitoring and spirometry recommended to document variability in airflow limitation 3, 4

Initial Management Approach

  • The American Academy of Allergy, Asthma, and Immunology recommends short-acting beta-agonists (SABA) such as albuterol for symptom relief, with consideration of daily inhaled corticosteroids (ICS) as controller therapy for persistent symptoms 2, 5
  • For children 0-4 years with recurrent wheezing triggered by respiratory infections, the American Academy of Pediatrics suggests considering a short course of daily ICS at the onset of respiratory tract infection with as-needed SABA 5

Monitoring and Assessment

  • Regular monitoring of peak flow or spirometry is essential to assess response to treatment, with a 20% or greater variability in PEF with a minimum change of at least 60 L/min highly suggestive of asthma, even in the absence of wheezing 3, 4
  • If symptoms persist despite treatment, the American Thoracic Society recommends considering bronchoprovocation testing to confirm airway hyperresponsiveness 2

Management of Specific Presentations

  • The American Academy of Allergy, Asthma, and Immunology suggests that when cough is the predominant symptom without wheeze, treatment is similar to classic asthma with inhaled corticosteroids and bronchodilators, with response to asthma medications confirming the diagnosis 2

Treatment Adjustments

  • If symptoms persist despite standard therapy, the American Academy of Allergy, Asthma, and Immunology recommends considering increasing the dose of inhaled corticosteroids, adding a long-acting beta-agonist (LABA) for patients ≥4 years with moderate to severe persistent symptoms, or subcutaneous immunotherapy for patients ≥5 years with allergic asthma 2, 5

Common Pitfalls and Caveats

  • The American Thoracic Society notes that absence of wheezing does not exclude reactive airway disease, and normal lung function between episodes does not rule out reactive airway disease, with overreliance on bronchodilators without addressing underlying inflammation potentially leading to poor symptom control 1, 2, 3, 4